Moderna (MRNA) Stock News

Tempus will manage sample collection and NGS services to support potential commercialization of intismeran autogene for melanoma and other cancers. Financial terms not disclosed.

A mysterious death at a Russian plague research lab sent Moderna and Novavax stocks swinging. After rallying Monday on plague speculation, both reversed sharply Tuesday after the WHO said the risk is low. Russian health officials deny a lab leak or plague infection.

Moderna (MRNA) will join the Nasdaq-100, replacing Warner Bros. Discovery (WBD), following a more than 500% surge in its stock price this year. The move is driven by Moderna's market-cap growth and is expected to trigger passive fund flows.

Citi downgraded MRNA to Sell from Neutral, raising its price target to $80 from $60 but arguing the stock's 222% rally since interim INTerpath-001 results has pushed valuation too far. The bank says the roughly $80B market cap implies success across multiple cancer indications, and even assuming 100% success for intismeran's lead programs, the stock is worth only about $100/share. To justify roughly $200/share, intismeran would need about $26B in annual cancer sales—nearly 7x Citi's forecast. Citi still sees intismeran as a potential leading melanoma treatment but says investors now need strong efficacy and consistency data.

Moderna appointed Juan Andres as COO, effective October 5, 2026. Andres, who previously led the company's COVID-19 vaccine manufacturing scale-up, will receive an $800,000 base salary, a 90% bonus target, and a $5 million equity grant. Jerh Collins, Chief Technical Operations and Quality Officer, is retiring.

Moderna shares have gained nearly 575% this year, on track for a record annual performance. The move follows positive Phase 3 data for its personalized mRNA cancer vaccine in melanoma, co-developed with Merck.

Moderna CEO Stéphane Bancel said at a Wall Street Journal event that AI-driven bioterrorism is his top concern. He described a scenario where a bad actor uses AI to cheaply build a respiratory virus as having a very high probability of happening.

Moderna CEO Stéphane Bancel told Bernstein’s healthcare conference the company is an mRNA platform business, not just a Covid vaccine maker. The stock touched a 52-week high of $192.31 intraday before closing down 0.3% on a weak market day. Upcoming data presentations at ESMO in late October are the next catalyst.

AMD, Moderna, WBD among stocks hitting 52-week highs.

Rothschild Redburn downgraded Moderna (MRNA) to Sell with an $81 price target. The analyst called the Phase 3 melanoma vaccine result 'a great result' but said the stock now appears to price in broad use across multiple tumor types where there is little or no supporting data.

Moderna is raising $2B via convertible senior notes due 2032, with an option for an extra $300M. The FDA also approved its updated 2026-2027 COVID-19 vaccines, including the new MnExSpike formula.

An 87-year-old melanoma trial participant bought Moderna (MRNA) stock when he enrolled in an experimental mRNA cancer vaccine study two years ago, per WSJ. The stock rose more than 150% last week on successful trial results.

Ro Khanna bought Moderna stock in June; shares surged in August on trial results.

Trump bought Moderna, $MRNA. He bought up to $50,000 of $MRNA on March 2, bought again on March 17, and only partially sold in May. It was up more than 150% yesterday.

An unverified report claims Moderna shares dropped 18%. No further details are available. The source is unconfirmed.

Merck and Moderna announced positive Phase 3 results for intismeran autogene, an mRNA personalized cancer vaccine, combined with Keytruda in melanoma. The trial met recurrence-free and distant metastasis-free survival endpoints. Full data to be presented at a medical meeting; regulatory submissions to begin.

Moderna and Merck reported their personalized mRNA cancer vaccine succeeded in a Phase 3 trial for melanoma. AI reportedly helped design the vaccine.

FDA approves Moderna's first mRNA flu vaccine.